Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine

Iron overload is a serious problem for some maintenance hemodilaysis (MHD) patients and may be manifest by organ dysfunction [1] and elevated serum ferritin levels [2]. We had the opportunity to study iron chelation therapy in an iron overloaded dialysis patient during MHD and subsequently during continuous ambulatory peritoneal dialysis (CAPD) treatment and to determine the effectiveness of iron removal using intravenous and intraperitoneal deferoxamine mesylate (Des-ferol®, Ciba-Giegy, Summit, New Jersey)